AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03917433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
Study NCT03917433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile Feedback
Description: In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
Study NCT03917433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Point-based Rewards
Description: Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
Study NCT04644783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test assay
Description: Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
Study NCT04110600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee effect on early gastric motility
Description: this group 100ml coffee after two hours
Study NCT04110600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy pepper mint oil on motility
Description: This group 100me pepper mint oil after 2 hours
Study NCT04972747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin care with sunflower oil
Description: The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
Study NCT01363414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate
Description: one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
Study NCT01363414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: one drop of sterile 0.9% sodium chloride solution in the other eye
Study NCT03221764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone with CoSeal
Description: CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
Study NCT03221764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 driver
Description: The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
Study NCT03969992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroFact
Description: Aerosolized SF-RI 1
Study NCT03969992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP
Description: nCPAP (nasal continuous positive airway pressure) alone
Study NCT02793128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-101 instillations
Description: Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
Study NCT04958915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Knee joint 30° flexion scan
Description: The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
Study NCT03921879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-82 Dose Escalation
Description: The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
Study NCT03921879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-82 Dose Expansion
Description: A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT03769168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Study NCT04150133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Residue Diet
Description: Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
Study NCT04150133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Residue Diet
Description: Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
Study NCT00881751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00881751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00881751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: Given orally
Study NCT01988376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surepath
Description: A liquid-base method of Pap smear for screening the recurrence of cervical cancer
Study NCT01988376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pap smear
Description: Conventional Pap smear
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanthanum Carbonate
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Nicotinamide)
Description: Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for lanthanum carbonate)
Description: Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
Study NCT02258074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for lanthanum carbonate)
Description: Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
Study NCT01814904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-L
Description: body surface area equivalent (BSAeq) 3 g/day
Study NCT01814904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-M
Description: BSAeq 6 g/day
Study NCT00378079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling Only
Description: Counseling only in prison, with passive referral to drug abuse treatment upon release
Study NCT00378079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling + Transfer
Description: Counseling only in prison, with opportunity to enter methadone maintenance upon release
Study NCT00378079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling + Methadone
Description: Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
Study NCT00546221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support exercise programme
Description: The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
Study NCT00546221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed exercise
Description: This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
Study NCT03348397 — intervention group
Intervention type: PROCEDURE
Intervention: right ventricular outflow tract reconstruction with contegra
Description: Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
Study NCT03348397 — intervention group
Intervention type: PROCEDURE
Intervention: right ventricular outflow tract reconstruction with pulmonary homograft
Description: cryopreserved pulmonary homografts
Study NCT00620035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopaque Etonogestrel Implant
Description: One implant inserted for a 3-year treatment period
Study NCT03434509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Tai Chi and Mindful Movement classes
Description: Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing).
Study NCT04331171 — intervention group
Intervention type: DEVICE
Intervention: Web application users
Description: questionnaire of comorbidity and symptoms completed by the patient on his smartphone
Study NCT01642121 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02510755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study NCT00805233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination ranibizumab + bromfenac
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
Study NCT04475848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
Study NCT04531072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study NCT04531072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study NCT02379897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Study NCT00805233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab injection alone
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
Study NCT03318419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5mg/㎡ d1-5
Study NCT03318419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300ug d0-14
Study NCT03318419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/㎡ q12h SC d1-14
Study NCT03318419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500U/m2 im d1
Study NCT02264041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilobradine, low dose
Study NCT02264041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, low dose
Study NCT02264041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilobradine, high dose
Study NCT02264041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, high dose
Study NCT02264041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02392715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with Threshold by respironics
Description: Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax.
Study NCT02392715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory muscle training
Description: with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)
Study NCT01814904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-H
Description: BSAeq 9 g/day
Study NCT01814904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBPB
Study NCT01321567 — intervention group
Intervention type: DRUG
Intervention: rabeprazole sodium
Description: Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
Study NCT02393014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple physical exercises
Description: 1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not.
Study NCT02114788 — intervention group
Intervention type: OTHER
Intervention: Internet-based
Study NCT02007733 — intervention group
Intervention type: OTHER
Intervention: Serial Weights
Description: We will collect serial weights on all children enrolled in this study.
Study NCT02007733 — intervention group
Intervention type: OTHER
Intervention: IVC/Aorta Ultrasound
Description: We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
Study NCT02007733 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
Study NCT01051349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: Administered as specified in the treatment arm.
Study NCT01051349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent seasonal influenza vaccine
Description: All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
Study NCT00611676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
Study NCT01968551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study NCT01968551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg tablet administered orally once daily
Study NCT01968551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline DRV- containing ARV regimen
Description: Participants will take their baseline DRV- containing ARV regimen as prescribed.
Study NCT01916239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard pomegranate extract formulation
Description: Standard pomegranate extract formulation containing 20% punicalagin
Study NCT01916239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract formulation-1
Description: New pomegranate extract formulation-1
Study NCT01916239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract formulation-2
Description: New pomegranate extract formulation-2
Study NCT01769898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol-budesonide
Description: Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
Study NCT01769898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol-budesonide
Description: Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
Study NCT01842178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control.
Study NCT01842178 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scratching
Description: Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control.
Study NCT04169347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 2 week cycles
Study NCT04551339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreserVision AREDS formulation soft gels or tablets
Description: Two tabs taken daily for three months
Study NCT04551339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin with 11mg of zinc
Description: One tab taken daily for three months
Study NCT03374618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
Study NCT00863460 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: cranial radiotherapy
Description: 40 Gy
Study NCT00863460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive chemotherapy and hematopoietic stem cell rescue
Description: intensive chemotherapy and hematopoietic stem cell rescue
Study NCT00863460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX based chemotherapy
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
Study NCT00863460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX based chemotherapy
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
Study NCT03426007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).